Biotricity (BTCY)
(Delayed Data from OTC)
$0.39 USD
-0.04 (-9.30%)
Updated Aug 26, 2024 03:59 PM ET
3-Hold of 5 3
C Value B Growth D Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BTCY 0.39 -0.04(-9.30%)
Will BTCY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BTCY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BTCY
Biotricity (BTCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Here Is Why Bargain Hunters Would Love Fast-paced Mover Biotricity Inc. (BTCY)
BTCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are Medical Stocks Lagging HCA Healthcare (HCA) This Year?
Biotricity Inc. (BTCY) Upgraded to Buy: Here's What You Should Know
Biotricity Inc. (BTCY) Reports Q3 Loss, Misses Revenue Estimates
Other News for BTCY
Biotricity reports Q1 results
BTCY Stock Earnings: Biotricity Reported Results for Q1 2025
LOBO EV and Nexalin Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Biotricity announces margin improvement driven by AI Cloud platform
Biotricity Announces Continued Margin Improvement Driven by its Proprietary AI Cloud